J. Eugene Huffstutter

553 total citations
15 papers, 435 citations indexed

About

J. Eugene Huffstutter is a scholar working on Rheumatology, Hematology and Epidemiology. According to data from OpenAlex, J. Eugene Huffstutter has authored 15 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 5 papers in Hematology and 4 papers in Epidemiology. Recurrent topics in J. Eugene Huffstutter's work include Rheumatoid Arthritis Research and Therapies (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Systemic Lupus Erythematosus Research (4 papers). J. Eugene Huffstutter is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (6 papers), Autoimmune and Inflammatory Disorders Research (5 papers) and Systemic Lupus Erythematosus Research (4 papers). J. Eugene Huffstutter collaborates with scholars based in United States, France and Taiwan. J. Eugene Huffstutter's co-authors include E. Carwile LeRoy, Edwin A. Smith, C B Loadholt, M. Bashar Kahaleh, Frank DeLustro, Patrick Durez, Michael Schiff, S. Kelly, Vicente Rodríguez‐Valverde and Mark C. Genovese and has published in prestigious journals such as JAMA, Annals of Internal Medicine and Annals of the Rheumatic Diseases.

In The Last Decade

J. Eugene Huffstutter

14 papers receiving 418 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Eugene Huffstutter United States 10 223 178 111 109 69 15 435
Paola Adele Lonati Italy 12 184 0.8× 163 0.9× 191 1.7× 95 0.9× 70 1.0× 21 481
J.‐B. Monfort France 12 121 0.5× 94 0.5× 97 0.9× 34 0.3× 59 0.9× 30 396
Stephen C. Foster United States 11 250 1.1× 128 0.7× 97 0.9× 62 0.6× 17 0.2× 25 603
Manuel Almagro Spain 13 73 0.3× 94 0.5× 73 0.7× 92 0.8× 134 1.9× 49 473
Walter L. Binder United States 13 262 1.2× 90 0.5× 112 1.0× 131 1.2× 21 0.3× 24 483
Kara Heelan United Kingdom 11 157 0.7× 210 1.2× 35 0.3× 48 0.4× 36 0.5× 27 342
Tai Muryoi Japan 16 183 0.8× 174 1.0× 256 2.3× 37 0.3× 50 0.7× 32 552
Youri Chanseaud France 12 92 0.4× 159 0.9× 120 1.1× 53 0.5× 45 0.7× 13 379
Sumie Tabata Japan 13 46 0.2× 141 0.8× 113 1.0× 101 0.9× 28 0.4× 49 449
D. Gilbert France 16 369 1.7× 442 2.5× 158 1.4× 134 1.2× 52 0.8× 44 711

Countries citing papers authored by J. Eugene Huffstutter

Since Specialization
Citations

This map shows the geographic impact of J. Eugene Huffstutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Eugene Huffstutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Eugene Huffstutter more than expected).

Fields of papers citing papers by J. Eugene Huffstutter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Eugene Huffstutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Eugene Huffstutter. The network helps show where J. Eugene Huffstutter may publish in the future.

Co-authorship network of co-authors of J. Eugene Huffstutter

This figure shows the co-authorship network connecting the top 25 collaborators of J. Eugene Huffstutter. A scholar is included among the top collaborators of J. Eugene Huffstutter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Eugene Huffstutter. J. Eugene Huffstutter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Winthrop, Kevin, John A. Hawkins, Adriana Weinberg, et al.. (2024). POS0620 IMMUNOGENICITY OF THE RECOMBINANT ZOSTER VACCINE IN PEOPLE WITH RHEUMATOID ARTHRITIS USING ABATACEPT. Annals of the Rheumatic Diseases. 83. 764–765.
2.
Combe, Bernard, Tsen‐Fang Tsai, J. Eugene Huffstutter, et al.. (2021). Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. Arthritis Research & Therapy. 23(1). 41–41. 13 indexed citations
3.
Curtis, Jeffrey R., Stacey S. Cofield, S. Louis Bridges, et al.. (2021). The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. Annals of Internal Medicine. 174(11). 1510–1518. 19 indexed citations
4.
Combe, Bernard, Tsen‐Fang Tsai, J. Eugene Huffstutter, et al.. (2019). SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT. Annals of the Rheumatic Diseases. 78. 1270–1271. 1 indexed citations
5.
Huffstutter, J. Eugene, Shelly Kafka, Lawrence H. Brent, et al.. (2016). Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study. Current Medical Research and Opinion. 33(4). 657–666. 10 indexed citations
6.
Huffstutter, J. Eugene, et al.. (2012). Hypercalcemia from sarcoidosis successfully treated with infliximab.. PubMed. 29(1). 51–2. 10 indexed citations
7.
Huffstutter, J. Eugene, James C. Taylor, Joy Schechtman, et al.. (2011). Single- versus dual-infusion of B-cell-depleting antibody ocrelizumab in rheumatoid arthritis: results from the Phase III FEATURE trial. International Journal of Clinical Rheumatology. 6(6). 689–696. 5 indexed citations
8.
Schiff, Michael, J. Eugene Huffstutter, Vicente Rodríguez‐Valverde, et al.. (2008). The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Annals of the Rheumatic Diseases. 68(11). 1708–1714. 123 indexed citations
9.
Huffstutter, J. Eugene, et al.. (2007). A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis. Current Medical Research and Opinion. 23(8). 1967–1979. 7 indexed citations
10.
Hawkins, Stephen, et al.. (2007). Cutaneous Mucormycosis Complicating Methotrexate, Prednisone, and Infliximab Therapy. JCR Journal of Clinical Rheumatology. 13(6). 361–362. 10 indexed citations
11.
Huffstutter, J. Eugene, et al.. (2004). Treatment of Resistant Adult Still Disease With Infliximab. JCR Journal of Clinical Rheumatology. 10(4). 218–221. 9 indexed citations
12.
Shergy, William, J. Eugene Huffstutter, Allan L. Goldman, et al.. (2002). Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.. PubMed. 29(4). 667–77. 58 indexed citations
13.
Huffstutter, J. Eugene. (1998). Accuracy of Physicians' Office Laboratory Results. JAMA. 280(2). 129–129. 2 indexed citations
14.
Kahaleh, M. Bashar, et al.. (1987). A modified scleroderma skin scoring method.. PubMed. 4(4). 367–9. 124 indexed citations
15.
Huffstutter, J. Eugene, Frank DeLustro, & E. Carwile LeRoy. (1985). Cellular immunity to collagen and laminin in scleroderma. Arthritis & Rheumatism. 28(7). 775–780. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026